These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33046405)

  • 41. Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus.
    Chang YH; Hwu DW; Chang DM; An LW; Hsieh CH; Lee YJ
    Acta Diabetol; 2017 Jun; 54(6):561-568. PubMed ID: 28331986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
    Thalange N; Deeb L; Iotova V; Kawamura T; Klingensmith G; Philotheou A; Silverstein J; Tumini S; Ocampo Francisco AM; Kinduryte O; Danne T
    Pediatr Diabetes; 2015 May; 16(3):164-76. PubMed ID: 25683037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
    Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
    Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment-Induced Neuropathy of Diabetes (TIND) in Pediatrics: A Case Report and Review of the Literature.
    Chandler E; Brown M; Wintergerst K; Doll E
    J Clin Endocrinol Metab; 2020 Feb; 105(2):. PubMed ID: 31613321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.
    Braun D; Konrad D; Lang-Muritano M; Schoenle E
    Pediatr Diabetes; 2008 Aug; 9(4 Pt 2):382-7. PubMed ID: 18331413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment induced neuropathy of diabetes.
    Gibbons CH
    Auton Neurosci; 2020 Jul; 226():102668. PubMed ID: 32247944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes.
    Herring R; Knight R; Shojaee-Moradie F; Johnsen S; Umpleby AM; Jackson N; Jones R; Dijk DJ; Russell-Jones DL
    Diabetes Obes Metab; 2015 Nov; 17(11):1100-3. PubMed ID: 26272173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2).
    Wheeler MD; Barrientos-Perez M; Lo FS; Liang B; Lunsford A; Thórisdóttir Ó; Zuckerman-Levin N
    Eur J Pediatr; 2018 Oct; 177(10):1497-1503. PubMed ID: 30014302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes.
    Home P; Baik SH; Gálvez GG; Malek R; Nikolajsen A
    J Med Econ; 2015 Mar; 18(3):230-40. PubMed ID: 25407031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes.
    Turner D; Luzio S; Gray BJ; Bain SC; Hanley S; Richards A; Rhydderch DC; Martin R; Campbell MD; Kilduff LP; West DJ; Bracken RM
    Diabet Med; 2016 Apr; 33(4):506-10. PubMed ID: 26220149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF; Dornhorst A; Sreenan S;
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
    Szypowska A; Golicki D; Groele L; Pańkowska E
    Pol Arch Med Wewn; 2011; 121(7-8):237-46. PubMed ID: 21878861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus.
    Kalirai S; Stephenson J; Perez-Nieves M; Grabner M; Hadjiyianni I; Geremakis C; Pollom RD; Reed B; Fisher L
    Prim Care Diabetes; 2018 Apr; 12(2):155-162. PubMed ID: 29100717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.